It should therefore be considered whether such compounds could be beneficial for tumor patients receiving chemotherapy, even if they are also receiving anti-VEGF drugs as the ones in clinical use today do not reduce the side-effects associated with chemotherapy. This evidence concerns the gene VEGFA and neoplasm.